Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Interim report of a phase 1/2 study of ESG206 in patients with refractory or relapsed primary immune thrombocytopenia

Yu Hou, Xiaolin Zhang, Hu Zhu et al. Nov 03, 2025 pp. 3039-3039 10.1182/blood-2025-3039

Abstract Introduction: Blockade of the BAFF-R signaling pathway and depletion of BAFF-R–expressing B cells may offer clinical benefit to pat...

Fertility preservation in AYA oncology: Provider knowledge gaps, counseling practices, and barriers to care

Anjani Kapadia, Sang Mee Lee, Lindsay Schwartz Nov 03, 2025 pp. 2865-2865 10.1182/blood-2025-2865

Abstract Background: In the United States, nearly 90,000 adolescents and young adults (AYAs) aged 15–39 are diagnosed with cancer annually....

Eltrombopag promotes hematopoietic engraftment and improves the survival of bone marrow failure disease following hematopoietic stem cell transplantation

Meng Zhou, Qian Zhu, Lu Zhou et al. Nov 03, 2025 pp. 1424-1424 10.1182/blood-2025-1424

Abstract Background Bone marrow failure disease (BMFD) arises from congenital or acquired hematopoietic stem cell dysfunction, characterized...

Rituximab plus lenalidomide (R²) versus standard therapies in follicular lymphoma: A systematic review and meta-analysis of randomized controlled trials

Abat Khan, Name: Iftikhar Khan, Moosa Mubarika et al. Nov 03, 2025 pp. 1828-1828 10.1182/blood-2025-1828

Abstract Introduction: Follicular lymphoma (FL) is a common indolent non-Hodgkin lymphoma characterized by frequent rela...

AI-based decision support (M-BOT) for treatment selection in multiple myeloma

Alexander Luchinin, Anastasia Semenova, Tigran Gevorkyan et al. Nov 03, 2025 pp. 5770-5770 10.1182/blood-2025-5770

Abstract Background: Therapeutic decision-making in hematology, particularly for patients with multiple myeloma (MM), is often characterized...

A multicenter real-world analysis (RWA) of primary cutaneous anaplastic large cell lymphoma (PCALCL) treated in the era of targeted therapies

Deepa Jagadeesh, Stefan Barta, Seunghee Margevicius et al. Nov 03, 2025 pp. 5433-5433 10.1182/blood-2025-5433

Abstract Introduction: The real-world outcomes in patients (pts) with PCALCL in the era of targeted therapies like Brentuximab Vedotin (BV)...

Identification of persister cells and evolution of tumor clones during immunotherapy and at minimal residual disease timepoints decoded by single-cell whole-genome sequencing in multiple myeloma

Rosa Toenges, Jean-Baptiste Alberge, Tomoki Iemura et al. Nov 03, 2025 pp. 3930-3930 10.1182/blood-2025-3930

Abstract Background: Mutations in cancer driver genes and target antigens are associated with poor prognosis in multiple myeloma (MM), but th...

Parental replacement therapy with iron dextran or ferumoxytol in patients with iron defiency

Joseph Kuruvilla, Muneer Khan, Sundeep Bekal et al. Nov 03, 2025 pp. 6463-6463 10.1182/blood-2025-6463

Abstract Background: Replacement therapy in patients with iron deficiency can be administered via oral or parenteral route. Two intravenous...

Superior outcome from frontline cord blood transfusion combined HLA-full-matched unrelated donor hematopoietic stem cell transplantation for aplastic anemia

Xinru Jia, Tonglin Hu, Chuanao Xin et al. Nov 03, 2025 pp. 2512-2512 10.1182/blood-2025-2512

Abstract Aplastic anemia (AA) is a bone marrow failure syndrome caused by aberrant immune responses and is associated with high mortality an...

Snh-119014, a novel pyruvate kinase activator, enhances ATP production and reduces oxidative stress in erythroid cells from patients with β-thalassemia major

Huang Qiulin, Yumei Huang, Lingyuan Pan et al. Nov 03, 2025 pp. 4698-4698 10.1182/blood-2025-4698

Abstract Introduction: Oxidative stress contributes significantly to ineffective erythropoiesis and reduced red blood cell (RBC) survival in...

A protein S-targeting monoclonal antibody, VGA039, improves both primary and secondary hemostatic activity of von Willebrand disease patient blood in an ex vivo vascularized hemostasis-on-a-chip

Yumiko Sakurai, Megan Brown, Yongzhi Qiu et al. Nov 03, 2025 pp. 3051-3051 10.1182/blood-2025-3051

Abstract Introduction: Protein S (PS) is a cofactor for two important endogenous anticoagulant proteins, tissue factor pathway inhibitor α (...

Five year follow-up of donor-derived CD7 CAR T-cell therapy for r/r T-cell acute lymphoblastic leukemia

Jing Pan, Shengnan Zhou, Zhuojun Ling Nov 03, 2025 pp. 4150-4150 10.1182/blood-2025-4150

Abstract Background:CAR T-cell therapy for B-cell leukemia has matured significantly. However, studies on the safety and efficacy of CAR-cel...

Impact of pre-transplant functional status and comorbidities on outcomes in individuals with multiple myeloma undergoing autologous hematopoietic cell transplantation

Sawyer Bawek, Matthew Burwinkel, Nisha Nair et al. Nov 03, 2025 pp. 5798-5798 10.1182/blood-2025-5798

Abstract Background: Multiple myeloma (MM) is a hematologic malignancy for which autologous hematopoietic cell transplantation (auto-HCT) in...

Chidamide-based epigenetic therapy for relapsed/refractory Acute Myeloid Leukemia

Qing Li, Yu Wu Nov 03, 2025 pp. 6982-6982 10.1182/blood-2025-6982

Abstract Introduction: Effective treatment options for relapsed or refractory acute myeloid leukemia (R/R AML) remain limited....

Synergizing sickle cell: Extending healthcare dollars through a specialized sickle cell program

Advith Suresh, Allan Bowen, Benjamin Buchholz et al. Nov 03, 2025 pp. 7885-7885 10.1182/blood-2025-7885

Abstract Hemoglobinopathy as a whole affects approximately 1.5% of Americans. Sickle Cell Disease (SCD) affects over 100,000 people in the U...

BNP promotes platelet activation and thrombosis via its receptor natriureticpeptide receptor-a (NPRA): A paradigm shift from biomarker to effector

Yan Zhang, Zhenyu Li, Fadi Khasawneh et al. Nov 03, 2025 pp. 419-419 10.1182/blood-2025-419

Abstract Background-B-type natriuretic peptide (BNP) is a cardiac-derived vasodilator and a well-established biomarker for heart failure. El...

Artificial intelligence for predicting transformation of monoclonal gammopathy of undetermined significance to multiple myeloma: A systematic review and meta-analysis

Tejaswi Vinjam, Raghavendra Akhil Bogabathina, Vishal Ravella Nov 03, 2025 pp. 7498-7498 10.1182/blood-2025-7498

Abstract Objectives The purpose of this study was to assess the empirical evidence of the efficacy of AI in predicting th...

Heterogeneous clinical outcomes within contemporary risk strata: A genomic reappraisal of 2022 ELN in AML

Fanqiao Meng, Yu Liu, Dongfeng Zeng Nov 03, 2025 pp. 6940-6940 10.1182/blood-2025-6940

Abstract Background: Acute myeloid leukemia (AML) remains a prognostically heterogeneous malignancy despite advances in molecular risk strat...

First-line pola-R-CHP in diffuse large B cell lymphoma: A single-center real-world data analysis

Jie Sun, Xiaohong Tan Nov 03, 2025 pp. 7212-7212 10.1182/blood-2025-7212

Abstract Objective: To evaluate the efficacy of first-line Pola-R-CHP therapy in patients with high-risk diffuse large B-cell lymphoma (DLBC...

Peripheral blood immune profiling in newly diagnosed multiple myeloma: Associations with MRD status and high-risk cytogenetics

Anuja Abhyankar, Janine Joseph, Nour Nassour et al. Nov 03, 2025 pp. 7464-7464 10.1182/blood-2025-7464

Abstract Background: Both cytogenetic risk and measurable residual disease (MRD) status are the most important clinicall...

Trial in progress: Treatment of CNS lymphoma with zanubrutinib and tislelizumab: A phase ib/II investigator-initiated study

Ross Salvaris, Colm Keane, Judith Trotman et al. Nov 03, 2025 pp. 1926-1926 10.1182/blood-2025-1926

Abstract Background: Outcomes of patients with relapsed / refractory (r/r) central nervous system (CNS) lymphoma are ext...

Peripheral circulating myeloma cells accurately identify bone marrow MRD positivity in multiple myeloma patients receiving CAR T or autologous transplant

Rahul Thakur, Toulon O'Connor, Cynthia DeWitt et al. Nov 03, 2025 pp. 4075-4075 10.1182/blood-2025-4075

Abstract Depth of response assessed by minimal residual disease (MRD) assays is an important prognostic factor in multiple myeloma (MM). Bon...

Anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma with extramedullary disease: Comparative outcomes and evolving strategies

Reema Anjum, Ummul Asfeen, Bhaswanth Bollu et al. Nov 03, 2025 pp. 7608-7608 10.1182/blood-2025-7608

Abstract BACKGROUND/OBJECTIVE: Extramedullary disease (EMD) in relapsed/refractory multiple myeloma (RRMM) has aggressiv...

Multi-omics analysis identifies neutrophil degranulation as a PSMD3-regulated pathway in FLT3-mutated AML

Idaly Olivas, Saeedeh Darvishi, Mayra Henry et al. Nov 03, 2025 pp. 6757-6757 10.1182/blood-2025-6757

Abstract Introduction: Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the aggressive accumulation of immature stem...

G6PD-deficiency is associated with improved survival in patients with AML treated with venetoclax and azacitidine

Shira Buchrits, Alon Rozental, Ofer Algor et al. Nov 03, 2025 pp. 6993-6993 10.1182/blood-2025-6993

Abstract Glucose-6-phosphate dehydrogenase (G6PD) deficiency impairs cellular redox balance through reduced NADPH production and is the most...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page